亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

医学 安慰剂 兴奋剂 胰高血糖素样肽1受体 利拉鲁肽 胰高血糖素样肽-1 双盲 内科学 糖尿病 药理学 内分泌学 2型糖尿病 受体 替代医学 病理
作者
Carel W. le Roux,Oren Steen,Kathryn Jean Lucas,Elena Startseva,Anna Unseld,Anita M. Hennige
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:12 (3): 162-173 被引量:81
标识
DOI:10.1016/s2213-8587(23)00356-x
摘要

Summary

Background

Obesity is a widespread and chronic condition that requires long-term management; research into additional targets to improve treatment outcomes remains a priority. This study aimed to investigate the safety, tolerability, and efficacy of glucagon receptor–GLP-1 receptor dual agonist survodutide (BI 456906) in obesity management.

Methods

In this randomised, double-blind, placebo-controlled, dose-finding phase 2 trial conducted in 43 centres in 12 countries, we enrolled participants (aged 18–75 years, BMI ≥27 kg/m2, without diabetes) and randomly assigned them by interactive response technology (1:1:1:1:1; stratified by sex) to subcutaneous survodutide (0·6, 2·4, 3·6, or 4·8 mg) or placebo once-weekly for 46 weeks (20 weeks dose escalation; 26 weeks dose maintenance). The primary endpoint was the percentage change in bodyweight from baseline to week 46. Primary analysis included the modified intention-to-treat population (defined as all randomly assigned patients who received at least one dose of trial medication and who had analysable data for at least one efficacy endpoint) and was based on the dose assigned at randomisation (planned treatment), including all data censored for COVID-19-related discontinuations; the sensitivity analysis was based on the actual dose received during maintenance phase (actual treatment) and included on-treatment data. Safety analysis included all participants who received at least one dose of study drug. The trial is registered with ClinicalTrials.gov (NCT04667377) and EudraCT (2020–002479–37).

Findings

Between March 30, 2021, and Nov 11, 2021, we enrolled 387 participants; 386 (100%) participants were treated (0·6 mg, n=77; 2·4 mg, n=78; 3·6 mg, n=77; 4·8 mg, n=77; placebo n=77) and 233 (60·4%) of 386 completed the 46-week treatment period (187 [61%] of 309 receiving survodutide; 46 [60%] of 77 receiving placebo). When analysed according to planned treatment, mean (95% CI) changes in bodyweight from baseline to week 46 were −6·2% (−8·3 to −4·1; 0·6 mg); −12·5% (−14·5 to −10·5; 2·4 mg); −13·2% (−15·3 to −11·2; 3·6 mg); −14·9% (−16·9 to −13·0; 4·8 mg); −2·8% (−4·9 to −0·7; placebo). Adverse events occurred in 281 (91%) of 309 survodutide recipients and 58 (75%) of 77 placebo recipients; these were primarily gastrointestinal in 232 (75%) of 309 survodutide recipients and 32 (42%) of 77 placebo recipients.

Interpretation

All tested survodutide doses were tolerated, and dose-dependently reduced bodyweight.

Funding

Boehringer Ingelheim.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
biubiubiu驳回了852应助
4秒前
AUGKING27完成签到 ,获得积分10
15秒前
18秒前
22秒前
25秒前
无语的诗柳完成签到 ,获得积分10
27秒前
nina完成签到 ,获得积分10
27秒前
远山淡影_cy完成签到,获得积分20
32秒前
康谨完成签到 ,获得积分10
41秒前
blenx完成签到,获得积分10
43秒前
1分钟前
小叶子完成签到 ,获得积分10
1分钟前
Liufgui应助徐悦月采纳,获得10
1分钟前
1分钟前
Dave完成签到,获得积分10
1分钟前
FashionBoy应助Dave采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
顾矜应助Emon采纳,获得10
1分钟前
2分钟前
2分钟前
芝麻完成签到,获得积分10
2分钟前
2分钟前
Dave发布了新的文献求助10
2分钟前
大模型应助芝麻采纳,获得10
2分钟前
2分钟前
jjjjj发布了新的文献求助10
2分钟前
Liufgui应助花凉采纳,获得20
2分钟前
biubiubiu发布了新的文献求助10
2分钟前
万能图书馆应助章鱼采纳,获得10
2分钟前
jjjjj完成签到,获得积分20
2分钟前
3分钟前
章鱼发布了新的文献求助10
3分钟前
牛八先生完成签到,获得积分10
3分钟前
3分钟前
孙燕应助jjjjj采纳,获得30
3分钟前
Liufgui应助花凉采纳,获得20
3分钟前
Ava关闭了Ava文献求助
3分钟前
科研通AI2S应助liudy采纳,获得10
3分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990045
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256334
捐赠科研通 3270943
什么是DOI,文献DOI怎么找? 1805146
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228